 Shanlee Davis
Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Klinefelter Syndrome | 13 | 2022 | 50 | 5.090 |
Why?
| | Turner Syndrome | 6 | 2023 | 45 | 3.490 |
Why?
| | Testosterone | 5 | 2022 | 343 | 1.480 |
Why?
| | Oxandrolone | 3 | 2018 | 8 | 1.340 |
Why?
| | Sex Chromosome Aberrations | 5 | 2023 | 51 | 1.090 |
Why?
| | Cardiovascular Diseases | 4 | 2022 | 1729 | 1.010 |
Why?
| | Anti-Mullerian Hormone | 2 | 2020 | 50 | 0.870 |
Why?
| | Puberty | 3 | 2020 | 137 | 0.860 |
Why?
| | XYY Karyotype | 2 | 2020 | 15 | 0.860 |
Why?
| | Testis | 3 | 2018 | 133 | 0.770 |
Why?
| | Monosomy | 1 | 2021 | 10 | 0.750 |
Why?
| | Disorders of Sex Development | 1 | 2021 | 35 | 0.730 |
Why?
| | Mitochondria, Muscle | 1 | 2021 | 93 | 0.720 |
Why?
| | Ovarian Reserve | 1 | 2020 | 13 | 0.710 |
Why?
| | Dyslipidemias | 1 | 2022 | 154 | 0.710 |
Why?
| | Sex Chromosome Disorders of Sex Development | 1 | 2020 | 9 | 0.710 |
Why?
| | Sex Chromosome Disorders | 1 | 2020 | 13 | 0.710 |
Why?
| | Inhibins | 1 | 2020 | 45 | 0.710 |
Why?
| | Metabolic Syndrome | 3 | 2020 | 324 | 0.700 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2020 | 30 | 0.700 |
Why?
| | Androgens | 2 | 2018 | 167 | 0.690 |
Why?
| | Body Composition | 3 | 2020 | 586 | 0.660 |
Why?
| | Child | 22 | 2023 | 18407 | 0.640 |
Why?
| | Electronic Health Records | 2 | 2023 | 799 | 0.590 |
Why?
| | Body Height | 1 | 2017 | 180 | 0.520 |
Why?
| | Adipose Tissue | 1 | 2019 | 558 | 0.520 |
Why?
| | Child Development | 1 | 2019 | 389 | 0.510 |
Why?
| | Infertility, Male | 1 | 2015 | 59 | 0.500 |
Why?
| | Hypokalemia | 1 | 2014 | 25 | 0.480 |
Why?
| | Hypertension | 1 | 2022 | 1058 | 0.460 |
Why?
| | Phenotype | 5 | 2023 | 2815 | 0.440 |
Why?
| | Diabetic Ketoacidosis | 1 | 2014 | 159 | 0.410 |
Why?
| | Muscle, Skeletal | 1 | 2021 | 1477 | 0.400 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 906 | 0.400 |
Why?
| | Adolescent | 15 | 2023 | 17862 | 0.400 |
Why?
| | Obesity | 2 | 2022 | 2524 | 0.380 |
Why?
| | Male | 23 | 2023 | 55729 | 0.380 |
Why?
| | Humans | 33 | 2023 | 115038 | 0.380 |
Why?
| | Aneuploidy | 4 | 2023 | 86 | 0.360 |
Why?
| | Case-Control Studies | 3 | 2021 | 3015 | 0.330 |
Why?
| | Estradiol | 2 | 2023 | 455 | 0.320 |
Why?
| | Female | 18 | 2023 | 59610 | 0.320 |
Why?
| | Mosaicism | 2 | 2021 | 60 | 0.310 |
Why?
| | Chromosomes, Human, X | 3 | 2023 | 60 | 0.310 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2010 | 364 | 0.270 |
Why?
| | Epilepsy | 1 | 2010 | 278 | 0.270 |
Why?
| | Chromosomes, Human, Y | 2 | 2021 | 14 | 0.270 |
Why?
| | Blood Glucose | 1 | 2014 | 1821 | 0.260 |
Why?
| | Sex Chromosomes | 2 | 2023 | 42 | 0.250 |
Why?
| | Double-Blind Method | 3 | 2018 | 1664 | 0.250 |
Why?
| | Karyotype | 2 | 2023 | 13 | 0.240 |
Why?
| | Cross-Sectional Studies | 5 | 2023 | 4411 | 0.240 |
Why?
| | Child, Preschool | 11 | 2023 | 9093 | 0.230 |
Why?
| | Y Chromosome | 1 | 2023 | 6 | 0.230 |
Why?
| | Follow-Up Studies | 3 | 2019 | 4420 | 0.220 |
Why?
| | Body Mass Index | 2 | 2020 | 1967 | 0.210 |
Why?
| | Azabicyclo Compounds | 1 | 2022 | 5 | 0.200 |
Why?
| | Oxadiazoles | 1 | 2022 | 32 | 0.200 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2022 | 32 | 0.200 |
Why?
| | Adrenal Hyperplasia, Congenital | 1 | 2022 | 28 | 0.200 |
Why?
| | Phosphocreatine | 1 | 2021 | 36 | 0.200 |
Why?
| | Adenosine Diphosphate | 1 | 2021 | 81 | 0.190 |
Why?
| | Genitalia | 1 | 2021 | 28 | 0.190 |
Why?
| | Prognosis | 2 | 2019 | 3334 | 0.180 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2023 | 194 | 0.180 |
Why?
| | Gonadotropins | 1 | 2020 | 37 | 0.180 |
Why?
| | Developmental Disabilities | 2 | 2016 | 238 | 0.170 |
Why?
| | Waist Circumference | 1 | 2020 | 123 | 0.170 |
Why?
| | Magnetoencephalography | 1 | 2020 | 104 | 0.170 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 310 | 0.170 |
Why?
| | Hypogonadism | 1 | 2020 | 75 | 0.170 |
Why?
| | Young Adult | 7 | 2023 | 10498 | 0.170 |
Why?
| | Trisomy | 1 | 2020 | 68 | 0.170 |
Why?
| | Genetic Association Studies | 1 | 2021 | 344 | 0.170 |
Why?
| | Inservice Training | 1 | 2020 | 107 | 0.170 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2021 | 482 | 0.160 |
Why?
| | Adenosine Triphosphate | 1 | 2021 | 431 | 0.160 |
Why?
| | Focal Dermal Hypoplasia | 1 | 2019 | 5 | 0.160 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2020 | 164 | 0.160 |
Why?
| | Failure to Thrive | 1 | 2019 | 32 | 0.160 |
Why?
| | Testicular Hormones | 1 | 2018 | 9 | 0.160 |
Why?
| | Motor Skills Disorders | 1 | 2018 | 23 | 0.160 |
Why?
| | Face | 1 | 2020 | 168 | 0.160 |
Why?
| | Mentors | 1 | 2020 | 158 | 0.160 |
Why?
| | Growth Disorders | 1 | 2019 | 78 | 0.160 |
Why?
| | Mentoring | 1 | 2020 | 101 | 0.150 |
Why?
| | Triglycerides | 1 | 2020 | 471 | 0.150 |
Why?
| | Overweight | 1 | 2022 | 474 | 0.150 |
Why?
| | Interprofessional Relations | 1 | 2020 | 251 | 0.150 |
Why?
| | Patient Acceptance of Health Care | 1 | 2023 | 679 | 0.150 |
Why?
| | Infant | 5 | 2021 | 7945 | 0.150 |
Why?
| | Eosinophilic Esophagitis | 1 | 2021 | 295 | 0.150 |
Why?
| | Infant, Newborn | 3 | 2020 | 5040 | 0.140 |
Why?
| | Cohort Studies | 3 | 2020 | 4904 | 0.140 |
Why?
| | Delivery of Health Care | 1 | 2023 | 835 | 0.140 |
Why?
| | X Chromosome Inactivation | 1 | 2016 | 21 | 0.140 |
Why?
| | Algorithms | 1 | 2023 | 1488 | 0.140 |
Why?
| | Speech Disorders | 1 | 2016 | 30 | 0.140 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 538 | 0.140 |
Why?
| | Truth Disclosure | 1 | 2016 | 39 | 0.130 |
Why?
| | Language Development Disorders | 1 | 2016 | 38 | 0.130 |
Why?
| | Risk | 1 | 2019 | 815 | 0.130 |
Why?
| | Genetic Counseling | 1 | 2016 | 66 | 0.130 |
Why?
| | Mitochondria | 1 | 2021 | 750 | 0.130 |
Why?
| | Registries | 1 | 2023 | 1763 | 0.130 |
Why?
| | Transcription Factors | 1 | 2023 | 1531 | 0.130 |
Why?
| | Body Weight | 1 | 2019 | 873 | 0.130 |
Why?
| | Adult | 7 | 2022 | 30654 | 0.130 |
Why?
| | Child Behavior Disorders | 1 | 2016 | 131 | 0.120 |
Why?
| | Child Behavior | 1 | 2017 | 219 | 0.120 |
Why?
| | Sex Factors | 1 | 2019 | 1721 | 0.120 |
Why?
| | Muscle Strength | 1 | 2017 | 271 | 0.120 |
Why?
| | Potassium | 1 | 2014 | 128 | 0.120 |
Why?
| | Severity of Illness Index | 3 | 2017 | 2551 | 0.110 |
Why?
| | Insulin Resistance | 1 | 2021 | 1077 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 2108 | 0.110 |
Why?
| | Polymorphism, Genetic | 1 | 2016 | 617 | 0.110 |
Why?
| | Longitudinal Studies | 1 | 2019 | 2389 | 0.110 |
Why?
| | Quality of Life | 1 | 2023 | 2359 | 0.110 |
Why?
| | Autism Spectrum Disorder | 1 | 2017 | 322 | 0.100 |
Why?
| | Hypoglycemia | 1 | 2016 | 385 | 0.100 |
Why?
| | Biomarkers | 2 | 2022 | 3419 | 0.090 |
Why?
| | Treatment Outcome | 3 | 2022 | 9122 | 0.090 |
Why?
| | Cognition | 1 | 2017 | 983 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1523 | 0.090 |
Why?
| | Neoplasms | 1 | 2023 | 2106 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 1006 | 0.080 |
Why?
| | Quality Improvement | 1 | 2016 | 953 | 0.080 |
Why?
| | Brain | 1 | 2020 | 2379 | 0.080 |
Why?
| | Hospitalization | 1 | 2016 | 1754 | 0.070 |
Why?
| | Abnormalities, Multiple | 1 | 2008 | 177 | 0.070 |
Why?
| | Insulin | 1 | 2016 | 2082 | 0.070 |
Why?
| | Prevalence | 2 | 2023 | 2255 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2019 | 2098 | 0.060 |
Why?
| | Syndrome | 2 | 2020 | 337 | 0.060 |
Why?
| | Sexual Development | 1 | 2023 | 19 | 0.050 |
Why?
| | Karyotyping | 1 | 2023 | 102 | 0.050 |
Why?
| | Menarche | 1 | 2023 | 49 | 0.050 |
Why?
| | 17-alpha-Hydroxyprogesterone | 1 | 2022 | 3 | 0.050 |
Why?
| | Androstenedione | 1 | 2022 | 10 | 0.050 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2022 | 128 | 0.050 |
Why?
| | Prenatal Diagnosis | 1 | 2022 | 168 | 0.050 |
Why?
| | Mental Disorders | 1 | 2008 | 897 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2023 | 12547 | 0.040 |
Why?
| | Physicians, Women | 1 | 2020 | 55 | 0.040 |
Why?
| | Counseling | 1 | 2022 | 342 | 0.040 |
Why?
| | Administration, Oral | 1 | 2022 | 730 | 0.040 |
Why?
| | Morbidity | 1 | 2020 | 279 | 0.040 |
Why?
| | Genetic Testing | 1 | 2021 | 380 | 0.040 |
Why?
| | Peer Group | 1 | 2020 | 203 | 0.040 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3245 | 0.040 |
Why?
| | Gene Expression | 1 | 2023 | 1423 | 0.040 |
Why?
| | Minority Groups | 1 | 2020 | 228 | 0.040 |
Why?
| | Career Choice | 1 | 2020 | 181 | 0.040 |
Why?
| | Health Status | 1 | 2023 | 722 | 0.040 |
Why?
| | Universities | 1 | 2020 | 339 | 0.040 |
Why?
| | Social Media | 1 | 2020 | 133 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2022 | 1857 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1355 | 0.040 |
Why?
| | Occupational Exposure | 1 | 2020 | 256 | 0.040 |
Why?
| | Mental Health | 1 | 2023 | 559 | 0.040 |
Why?
| | Disability Evaluation | 1 | 2018 | 271 | 0.040 |
Why?
| | Social Support | 1 | 2020 | 528 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 678 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 126 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 342 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 334 | 0.030 |
Why?
| | Interpersonal Relations | 1 | 2017 | 339 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2016 | 477 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2017 | 913 | 0.030 |
Why?
| | Comorbidity | 1 | 2017 | 1457 | 0.030 |
Why?
| | Physicians | 1 | 2020 | 771 | 0.030 |
Why?
| | Pandemics | 1 | 2020 | 1321 | 0.030 |
Why?
| | Pregnancy | 1 | 2022 | 5519 | 0.020 |
Why?
| | Anxiety | 1 | 2017 | 845 | 0.020 |
Why?
| | Depression | 1 | 2017 | 1136 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1398 | 0.020 |
Why?
| | Middle Aged | 2 | 2022 | 26826 | 0.020 |
Why?
| | United States | 1 | 2020 | 12224 | 0.010 |
Why?
|
|
Davis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|